CytRx Calls for Removal of Stock from Berlin-Bremen Exchange
CytRx said this week that it has sent a formal demand letter to the Berlin-Bremen Stock Exchange requesting that the exchange delist the company’s common stock. According to CytRx, its stock was put on the exchange without its permission.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
